Epithelial-Related Antigen Antikörper

Antigen: Epithelial-Related Antigen

Klonalität: Monoklonal (MOC-311)

Wirt: Maus

Reaktivität: Human

Applikation: Immunhistochemie (IHC)

Zertifikate: ISO 9001:2008, ISO 13485:2003

Anbieter: Dako

Produktnummer: ABIN370636

Produktbeschreibung

Immunogen: Neuraminidase treated cells from a variant small-cell lung carcinoma cell line (GLS-1)1

Isotyp: IgG1, kappa chain

Klon: MOC-311

Beschreibung: Monoclonal antibody MOC-31 reacts with an epithelial antigen present on most normal and malignant epithelia. 1 At the Second International Workshop on Small-Cell Lung Cancer (SCLC) Antigens, MOC-31 was assigned to SCLC-Cluster 2, a group of antibodies which react with an epithelial antigen. The antigen characterized for another cluster 2 antibody (AUA 1) was shown to be a 40 kD transmembrane glycoprotein of unknown function. 2 Indirect immunotoxin screening assays have demonstrated that the cluster 2 antibodies, are effective in killing target cells. 2

Anwendungen

Applikationshinweise: Paraffin Sections Monoclonal antibody MOC-31 can be used on formalin-fixed, paraffin-embedded tissue sections. For optimal staining it is recommended that the deparaffinized tissue sections be treated with heat prior to the immunohistochemical staining procedure. For greater adherence of tissue sections to glass slides, the use of Silanized Slides (code S3003) is recommended. When using the water bath method, preheat a Coplin jar containing 0.01 mol/L citrate buffer, pH 6.0, as well as the water bath to 95-99 °C. When the temperature has stabilized, place tissue sections into the Coplin jar containing the preheated buffer. Heat the tissue sections for 40 minutes. For improved staining results and a shorter incubation time, Target Retrieval Solution (code S1700) can be used in place of the 0.01 mol/L citrate buffer. Under these conditions the incubation time in the water bath may be reduced to 20 minutes. After thermal treatment, allow the jar with buffer and slides to cool for 20 minutes at room temperature. Rinse well with tap water and place slides into buffer. Cryostat Sections and Cell Smears Monoclonal antibody MOC-31 can also be used to label cryostat sections or cell smears. Follow the recommended procedure for the detection system selected. (106945-002) 303331EFG_001 p. 2/4 Staining interpretation The cellular staining pattern for anti-MOC-31 is membranous. Normal Cells In immunohistochemical studies on cryostat tissue sections, MOC-31 was shown to react positively with glands and hairshafts in skin, pancreatic exocrine and endocrine glands, and epithelia of the digestive and respiratory tract, including the sero-mucous glands. Adrenal, ovary, brain, peripheral nerve and ganglion cells were unreactive with MOC-31. 3 On formalin-fixed, paraffin-embedded tissue sections, MOC- 31 staining was observed on the epithelia of kidney, endometrium, breast, liver and prostate and pancreatic acini, islets and ducts. MOC-31 was not observed to label normal peripheral blood or bone marrow. 4 Tumor Cells Cryostat sections of the following lung tumors were found to stain positively with MOC-31: 35/35 squamous cell carcinomas, 28/28 adenomas, 43/43 SCLC, 3/3 carcinoids, 5/5 adenocystic carcinomas, 1/1 carcinosarcoma, 1/1 mucoepidermal carcinoma and 1/1 pleomorphic adenoma. 4 MOC-31 has also been observed to stain tumor cells in pleural and peritoneal cytocentrifuge preparations of 58/59 adenocarcinomas. All 33 cases of reactive mesothelial hyperplasia and all five cases of malignant mesothelioma were found to be negative. 5 On formalin-fixed, paraffin-embedded tissue sections, presence of the MOC-31 antigen was immunohistochemically demonstrated on the following tumors: colon adenocarcinoma 2/2, gastric adenocarcinoma 2/2, esophageal-gastric adenocarcinoma 1/1, bladder transitional cell carcinoma 1/3, testicular yolk sac tumor 1/1, uterine papillary serous carcinoma 1/1, uterine mixed müllerian tumor 1/1, uterine adenomatoid tumor 1/1, ovary mucinous/endometrial cancer 1/1, ovary endometrioid carcinoma 1/1, serous carcinoma of the ovary 1/1, breast carcinoma 4/8, prostate adenocarcinoma 2/2, thyroid papillary carcinoma 1/1, thyroid medullary carcinoma 1/1, lung adenocarcinoma 2/2, lung bronchoalveolar carcinoma 1/1, lung squamous cell carcinoma 4/4, parathyroid adenoma 1/1, desmoplastic small cell tumor 1/1, pancreatic islet cell tumor 1/1, thymic carcinoid tumor 1/1, cholangiocarcinoma 1/1.

Buffer: MOC-31 is a mouse monoclonal antibody supplied in liquid form as tissue culture supernatant (containing fetal calf serum) dialyzed against 0.05 mol/L Tris-HCl, pH 7.2 and 0.015 mol/L sodium azide.

Lagerung: Store at 2-8 °C. Precautions: 1. For professional users. 2. This product contains sodium azide (NaN 3 ), a chemical highly toxic in pure form. At product concentrations, though not classified as hazardous, NaN 3 may react with lead and copper plumbing to form highly explosive build-ups of metal azides. Upon disposal, flush with large volumes of water to prevent metal azide build-up in plumbing. 3. As with any product derived from biological sources, proper handling procedures should be used. 4. Wear appropriate Personal Protective Equipment to avoid contact with eyes and skin. 5. Unused reagents should be disposed of according to local, State, and Federal regulations.

Beschränkungen: Für Forschungszwecke. Als CE-zertifizierter Antikörper in der Europäischen Union für In Vitro Diagnostik (IVD) zugelassen.

Publikationen

Publikationen: Johnston, Drake, Trepel et al.: "Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines." in: Cancer research, Vol. 52, Issue 16, pp. 4306-12, 1992 (PubMed).

Johnston, Liang, Henry et al.: "Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue." in: Cancer research, Vol. 51, Issue 24, pp. 6668-76, 1992 (PubMed).

Peters, van der Wilt, van Triest et al.: "Thymidylate synthase and drug resistance." in: European journal of cancer (Oxford, England : 1990), Vol. 31A, Issue 7-8, pp. 1299-305, 1995 (PubMed).

Johnston, Lenz, Leichman et al.: "Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors." in: Cancer research, Vol. 55, Issue 7, pp. 1407-12, 1995 (PubMed).

Johnston, Fisher, Rockette et al.: "The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 12, Issue 12, pp. 2640-7, 1995 (PubMed).

Pestalozzi, Peterson, Gelber et al.: "Prognostic importance of thymidylate synthase expression in early breast cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 15, Issue 5, pp. 1923-31, 1997 (PubMed).

Boku, Chin, Hosokawa et al.: "Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 4, Issue 6, pp. 1469-74, 1998 (PubMed).

Behan, Johnston, Allegra: "Epitope mapping of a series of human thymidylate synthase monoclonal antibodies." in: Cancer research, Vol. 58, Issue 12, pp. 2606-11, 1998 (PubMed).

Shiga, Heath, Rasmussen et al.: "Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 12, pp. 4097-104, 2000 (PubMed).

Paradiso, Simone, Petroni et al.: "Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients." in: British journal of cancer, Vol. 82, Issue 3, pp. 560-7, 2000 (PubMed).

Aschele, Debernardis, Tunesi et al.: "Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 6, Issue 12, pp. 4797-802, 2001 (PubMed).

Harpole, Moore, Herndon et al.: "The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 7, Issue 3, pp. 562-9, 2001 (PubMed).

Hu, Komorowski, Graewin et al.: "Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 9, Issue 11, pp. 4165-71, 2003 (PubMed).

Tabrizi, Kalloger, Koebel et al.: "Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases." in: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, Vol. 29, Issue 2, pp. 99-107, 2010 (PubMed).